Functional integration of protein A binding ability to antibody fragments for convenient and tag-free purification

References

• Kaplon H, Chenoweth A, Crescioli S, et al. Antibodies to watch in 2022. MAbs. 2022;14:2014296. PMID:35030985. doi: 10.1080/19420862.2021.2014296.
   PubMed Web of Science ®Google Scholar
• Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30(16):1443–15. PMID:8232330. doi: 10.1016/0161-5890(93)90106-L
   PubMed Web of Science ®Google Scholar
• Nuñez-Prado N, Compte M, Harwood S, et al. The coming of age of engineered multivalent antibodies. Drug Discov Today. 2015;20:588–594. doi: 10.1016/j.drudis.2015.02.013
   PubMed Web of Science ®Google Scholar
• Goulet DR, Atkins WM. Considerations for the design of antibody-based therapeutics. J Pharm Sci. 2020;109:74–103. PMID:31173761. doi: 10.1016/j.xphs.2019.05.031.
   PubMed Web of Science ®Google Scholar
• Unciti-Broceta JD, Del Castillo T, Soriano M, et al. Novel therapy based on camelid nanobodies. Ther Deliv. 2013;4(10):1321–1336. PMID:24116915. doi: 10.4155/tde.13.87.
   PubMedGoogle Scholar
• Shukla AA, Gupta P, Han X. Protein aggregation kinetics during protein a chromatography. Case study for an Fc fusion protein. J Chromatogr A. 2007;1171(1–2):22–28. PMID:17920607. doi: 10.1016/j.chroma.2007.09.040.
   PubMed Web of Science ®Google Scholar
• Chen W, Yuan Y, Jiang X. Antibody and antibody fragments for cancer immunotherapy. J Control Release. 2020;328:395–406. PMID:32853733. doi: 10.1016/j.jconrel.2020.08.021
   PubMed Web of Science ®Google Scholar
• Holliger P, Prospero T, Winter G. Diabodies: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA. 1993;90(14):6444–6448. doi: 10.1073/pnas.90.14.6444
   PubMed Web of Science ®Google Scholar
• Stork R, Campigna E, Robert B, et al. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem. 2009;284:25612–25619. doi: 10.1074/jbc.M109.027078
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell–engaging antibody. Science. 2008;321(5891):974–977. doi: 10.1126/science.1158545
   PubMed Web of Science ®Google Scholar
• Shahied LS, Tang Y, Alpaugh RK, et al. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem. 2004;279:53907–53914. doi: 10.1074/jbc.M407888200
   PubMed Web of Science ®Google Scholar
• Pörtner LM, Schönberg K, Hejazi M, et al. T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16. Cancer Immunol Immunother. 2012;61(10):1869–1875. doi: 10.1007/s00262-012-1339-9
   PubMed Web of Science ®Google Scholar
• Rathi C, Meibohm B. Clinical pharmacology of bispecific antibody constructs. J Clin Pharmacol. 2015;55:S21–8. doi: 10.1002/jcph.445
   PubMed Web of Science ®Google Scholar
• Mahmoudi Gomari M, Saraygord-Afshari N, Farsimadan M, et al. Opportunities and challenges of the tag-assisted protein purification techniques: applications in the pharmaceutical industry. Biotechnol Adv. 2020;45:107653. PMID:33157154. doi: 10.1016/j.biotechadv.2020.107653
   PubMed Web of Science ®Google Scholar
• Lykkemark S, Mandrup OA, Friis NA, et al. Degradation of C-terminal tag sequences on domain antibodies purified from E. coli supernatant. MAbs. 2014;6(6):1551–1559. PMID:25426869. doi: 10.4161/mabs.36211.
   PubMed Web of Science ®Google Scholar
• D’Huyvetter M, Vincke C, Xavier C, et al. Targeted radionuclide therapy with a 177Lu-labeled anti-HER2 nanobody. Theranostics. 2014;4(7):708–720. PMID:24883121. doi: 10.7150/thno.8156
   PubMed Web of Science ®Google Scholar
• Geisbrecht BV, Bouyain S, Pop M. An optimized system for expression and purification of secreted bacterial proteins. Protein Expr Purif. 2006;46:23–32. PMID:16260150. doi: 10.1016/j.pep.2005.09.003.
   PubMed Web of Science ®Google Scholar
• Munro S, Pelham HR. Use of peptide tagging to detect proteins expressed from cloned genes: deletion mapping functional domains of drosophila hsp 70. EMBO J. 1984;3:3087–3093. PMID:6526011. doi: 10.1002/j.1460-2075.1984.tb02263.x
   PubMed Web of Science ®Google Scholar
• Lee J, Kim M, Seo Y, et al. The catalytic activity of a recombinant single chain variable fragment nucleic acid-hydrolysing antibody varies with fusion tag and expression host. Arch Biochem Biophys. 2017;633:110–117. PMID:28888872. doi: 10.1016/j.abb.2017.09.004
   PubMed Web of Science ®Google Scholar
• Moks T, Abrahmsén L, Nilsson B, et al. Staphylococcal protein a consists of five IgG‐binding domains. Eur J Biochem. 1986;156:637–643. PMID:2938951. doi: 10.1111/j.1432-1033.1986.tb09625.x.
   PubMedGoogle Scholar
• Guss B, Uhlén M, Nilsson B, et al. Region X, the cell‐wall‐attachment part of staphylococcal protein a. Eur J Biochem. 1984;138(2):413–420. PMID:6697996. doi: 10.1111/j.1432-1033.1984.tb07931.x.
   PubMedGoogle Scholar
• Abrahmsén L, Moks T, Nilsson B, et al. Analysis of signals for secretion in the staphylococcal protein a gene. EMBO J. 1985;4:3901–3906. PMID:3912176. doi: 10.1002/j.1460-2075.1985.tb04164.x.
   PubMed Web of Science ®Google Scholar
• Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein a from Staphylococcus aureus at 2.9- and 2.8-Å resolution. Biochemistry. 1981;20(9):2361–2370. PMID:7236608. doi: 10.1021/bi00512a001.
   PubMed Web of Science ®Google Scholar
• Fahrner RL, Blank GS. Real-time monitoring of recombinant antibody breakthrough during protein a affinity chromatography. Biotechnol Appl Biochem. 1999;29(2):109–112. PMID:10075907. doi: 10.1111/j.1470-8744.1999.tb00539.x.
   PubMedGoogle Scholar
• Fahrner RL, Blank GS. Real-time control of antibody loading during protein a affinity chromatography using an on-line assay. J Chromatogr A. 1999;849(1):191–196. PMID:10444843. doi: 10.1016/S0021-9673(99)00539-7.
   PubMed Web of Science ®Google Scholar
• Graille M, Stura EA, Corper AL, et al. Crystal structure of a Staphylococcus aureus protein a domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc Natl Acad Sci U S A. 2000;97:5399–5404. PMID:10805799. doi: 10.1073/pnas.97.10.5399.
   PubMed Web of Science ®Google Scholar
• Henry KA, Sulea T, Van Faassen H, et al. A rational engineering strategy for designing protein a-binding camelid single-domain antibodies. PLoS One. 2016;11(9):e0163113. PMID:27631624. doi: 10.1371/journal.pone.0163113.
   PubMed Web of Science ®Google Scholar
• Crauwels M, Van Vaerenbergh N, Kulaya NB, et al. Reshaping nanobodies for affinity purification on protein a. N Biotechnol. 2020;57:20–28. PMID:32001339. doi: 10.1016/j.nbt.2020.01.005
   PubMed Web of Science ®Google Scholar
• Asano R, Kumagai T, Nagai K, et al. Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody. Protein Eng Des Sel. 2013;26:359–367. PMID:23468569. doi: 10.1093/protein/gzt009
   PubMed Web of Science ®Google Scholar
• Hutmacher C, Volta L, Rinaldi F, et al. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia. Leuk Res. 2019;84:106178. PMID:31326578. doi: 10.1016/j.leukres.2019.106178
   PubMed Web of Science ®Google Scholar
• Harwood SL, Alvarez-Cienfuegos A, Nuñez-Prado N, et al. ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy. Oncoimmunology. 2018;7:1–14. PMID:29296540. doi: 10.1080/2162402X.2017.1377874
   Web of Science ®Google Scholar
• Dong D, Zheng L, Lin J, et al. Structural basis of assembly of the human T cell receptor–CD3 complex. Nature. 2019;573:546–552. doi: 10.1038/s41586-019-1537-0
   PubMed Web of Science ®Google Scholar
• Asano R, Sone Y, Makabe K, et al. Humanization of the bispecific epidermal growth factor receptor × CD3 diabody and its efficacy as a potential clinical reagent. Clin Cancer Res. 2006;12(13):4036–4042. PMID:16818703. doi: 10.1158/1078-0432.CCR-06-0059.
   PubMed Web of Science ®Google Scholar
• Asano R, Kuroki Y, Honma S, et al. Comprehensive study of domain rearrangements of single-chain bispecific antibodies to determine the best combination of configurations and microbial host cells. MAbs. 2018;10(6):854–863. doi: 10.1080/19420862.2018.1476815
   PubMed Web of Science ®Google Scholar
• Studier FW. Protein production by auto-induction in high density shaking cultures. Protein Expr Purif. 2005;41(1):207–234. PMID:15915565. doi: 10.1016/j.pep.2005.01.016.
   PubMed Web of Science ®Google Scholar
• Asano R, Watanabe Y, Kawaguchi H, et al. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells. J Biol Chem. 2007;282:27659–27665. PMID:17644522. doi: 10.1074/jbc.M704719200
   PubMed Web of Science ®Google Scholar
• Saijyo S, Kudo T, Suzuki M, et al. Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med. 1995;177(1):61–71. PMID:8693487. doi: 10.1620/tjem.177.61.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Asano R, Arai K, et al. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody. Oncol Rep. 2011;26:949–955. PMID:21743971. doi: 10.3892/or.2011.1382
   PubMed Web of Science ®Google Scholar
• Kabat EA, Wu TT, Perry HM, et al. Foeller C.Sequences of proteins of immunological interest. National Institutes Of Health. 1991;1:1992–2719.
   Google Scholar
• Jansson B, Uhlén M, Nygren PA. All individual domains of staphylococcal protein a show fab binding. FEMS Immunol Med Microbiol. 1998;20(1):69–78. PMID:9514577. doi: 10.1111/j.1574-695X.1998.tb01112.x.
   PubMedGoogle Scholar
• Asano R, Ikoma K, Kawaguchi H, et al. Application of the Fc fusion format to generate tag-free bi-specific diabodies. FEBS J. 2010;277(2):477–487. PMID:20015073. doi: 10.1111/j.1742-4658.2009.07499.x
   PubMed Web of Science ®Google Scholar
• Crivianu-Gaita V, Thompson M. Aptamers, antibody scFv, and antibody fab’ fragments: an overview and comparison of three of the most versatile biosensor biorecognition elements. Biosens Bioelectron. 2016;85:32–45. PMID:27155114. doi: 10.1016/j.bios.2016.04.091
   PubMed Web of Science ®Google Scholar
• Zarrineh M, Mashhadi IS, Farhadpour M, et al. Mechanism of antibodies purification by protein a. Anal Biochem. 2020;609:113909. PMID:32827466. doi: 10.1016/j.ab.2020.113909
   PubMed Web of Science ®Google Scholar
• Oak E, Bartlett NL. Blinatumomab for the treatment of B-cell lymphoma. Expert Opin Investig Drugs. 2015;24(5):715–724. PMID:25739952. doi: 10.1517/13543784.2015.1021415.
   PubMed Web of Science ®Google Scholar
• Kjer-Nielsen L, Dunstone MA, Kostenko L, et al. Crystal structure of the human T cell receptor CD3εγ heterodimer complexed to the therapeutic mAb OKT3. Proc Natl Acad Sci U S A. 2004;101(20):7675–7680. PMID:15136729. doi: 10.1073/pnas.0402295101.
   PubMed Web of Science ®Google Scholar
• Asano R, Shimomura I, Konno S, et al. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics. MAbs. 2014;6(5):1243–1254. doi: 10.4161/mabs.29445. PMID:25517309.
   PubMed Web of Science ®Google Scholar
• Kuwahara A, Nagai K, Nakanishi T, et al. Functional domain order of an anti-egfr × anti-CD16 bispecific diabody involving nk cell activation. Int J Mol Sci. 2020;21(23):1–13. PMID:33255436. doi: 10.3390/ijms21238914.
   Web of Science ®Google Scholar